For the quarter ending 2025-09-30, RNAC has $372,675K in assets. $408,519K in debts. $143,384K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 143,384 | 160,324 | ||
| Accounts receivable | 722 | 354 | ||
| Prepaid expenses and other current assets | 3,154 | 2,717 | ||
| Total current assets | 147,260 | 163,395 | ||
| Property and equipment, net | 12,394 | 12,285 | ||
| Other assets | - | 5,551 | ||
| Right-of-use assets, net | 4,972 | 5,164 | ||
| In-process research and development assets | 150,600 | 150,600 | ||
| Goodwill | 48,163 | 48,163 | ||
| Long-term restricted cash | 1,735 | 1,735 | ||
| Investments | 2,000 | 2,000 | ||
| Long-term prepaid expenses and other assets | 5,551 | - | ||
| Total assets | 372,675 | 388,893 | ||
| Accounts payable | 2,225 | 454 | ||
| Accrued expenses and other current liabilities | 7,702 | 8,012 | ||
| Lease liabilities | 3,876 | 3,790 | ||
| Contingent value right liability | 0 | 0 | ||
| Total current liabilities | 13,803 | 12,256 | ||
| Lease liabilities, net of current portion | 8,727 | 9,559 | ||
| Warrant liabilities, net of current portion | - | 1,364 | ||
| Warrant liability | 848 | - | ||
| Contingent value right liability, net of current portion | 369,000 | 352,100 | ||
| Deferred tax liabilities, net | 16,141 | 16,141 | ||
| Total liabilities | 408,519 | 391,420 | ||
| Preferred stock, value, issued-Series APreferred Stock | 0 | 0 | ||
| Preferred stock, value, issued-Series BPreferred Stock | 0 | 0 | ||
| Preferred stock, value, issued | 0 | 0 | ||
| Common stock, 0.0001 par value 350,000,000 shares authorized as of september 30, 2025 and december 31, 2024 26,003,606 and 25,767,369 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 3 | 3 | ||
| Additional paid-in capital | 698,537 | 695,942 | ||
| Accumulated deficit | -729,797 | -693,895 | ||
| Accumulated other comprehensive loss | -4,587 | -4,577 | ||
| Total stockholders deficit | -35,844 | -2,527 | ||
| Total liabilities and stockholders deficit | 372,675 | 388,893 | ||
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)